<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233763</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4508</org_study_id>
    <nct_id>NCT03233763</nct_id>
  </id_info>
  <brief_title>Laboratory Studies Into the Pathology of Leukaemia</brief_title>
  <official_title>Laboratory Studies Into the Pathology of Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ongoing laboratory work into the pathology of Leukaemia:
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will test AML samples sent to the diagnostic laboratory from participants
      with newly diagnosed or relapsed/refractory AML. Samples will be sent from district general
      hospitals and teaching hospitals.

      Results will be returned to referring clinicians in the same way investigators currently
      return results for samples sent for standard tests. The service will be advertised through
      the Royal Marsden Website with visibility to both participants and HCPs). The investigators
      will also inform all the clinicians involved in the AML working party (Dr Taussig is a member
      of the AML working group).

      In addition we are looking at diagnostic approaches to IDH 1 and 2 mutation identification.

      An initial comparison of 50 samples by three analysis methods will be conducted.

      IDH1 and IDH2 variant discovery will first be performed using an established standard in
      house SOP (SOP: SMD103) for CE-SSCA
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathology of Leukaemia cells</measure>
    <time_frame>15 years</time_frame>
    <description>Pathology of Leukaemia cells</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Aspirate</intervention_name>
    <description>Diagnostic Bone Marrow aspirate</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone Marrow and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is an exploratory laboratory study using stored tissue where consent has already been
        given.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18 &amp; Over Diagnosis of AML Generic Research consent given

        Exclusion Criteria:

        Under 18 No generic research consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Taussig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonora Conneely</last_name>
    <phone>0208 661 3018</phone>
    <email>leonora.conneely@rmh.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Haematology, the Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonora Conneely</last_name>
      <phone>0208 661 3018</phone>
      <email>HaematoOncRn@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Taussig, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to patient tissue is via formal request to the Sponsor</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

